These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21550231)

  • 41. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical research: outlook from industry.
    Echols R
    Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
    [No Abstract]   [Full Text] [Related]  

  • 43. Health care cost control. Getting on the right track.
    Diede ML; Liliedahl R
    Manag Care; 2002 Feb; 11(2):24-5, 29-33. PubMed ID: 11904910
    [No Abstract]   [Full Text] [Related]  

  • 44. Time to fill the doughnuts--health care reform and Medicare Part D.
    Shrank WH; Choudhry NK
    N Engl J Med; 2011 Feb; 364(7):598-601. PubMed ID: 21247308
    [No Abstract]   [Full Text] [Related]  

  • 45. Improving efficiencies in pharmaceutical distribution channels using the economic order quantity model.
    Sullivan DL; Schommer JC
    Clin Ther; 1993; 15(6):1146-53; discussion 1120. PubMed ID: 8111811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Roundtable discussion. Cost justification of innovative drugs through assessment of total health care costs.
    Rybak MJ; Allen R; Craven PC; Freeman R; Nightingale CH; Normand C; Rubinstein E; Schaison GS; Whitelaw G
    Hosp Formul; 1993 Jan; 28 Suppl 1():33-6. PubMed ID: 10123836
    [No Abstract]   [Full Text] [Related]  

  • 47. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PBMs get new role. Seen as key to drug cost control under new benefit.
    Becker C
    Mod Healthc; 2003 Dec 22-29; 33(51):31, 33. PubMed ID: 14723089
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?
    Garattini L; Curto A; Freemantle N
    Pharmacoeconomics; 2016 May; 34(5):423-6. PubMed ID: 26820147
    [No Abstract]   [Full Text] [Related]  

  • 51. Using pharmacoeconomics to value pharmacotherapy.
    Hay JW
    Clin Pharmacol Ther; 2008 Aug; 84(2):197-200. PubMed ID: 18679182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmaceutical industry.
    Lewis L
    State Health Care Am; 1994; ():23-7. PubMed ID: 10133845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drugs: budget busters or cost cutters in future health care?
    Egger E
    Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640
    [No Abstract]   [Full Text] [Related]  

  • 54. Economist Conferences Ninth Annual Pharmaceuticals Conference. 12-13 February 2003, London, UK.
    Mayfield R
    IDrugs; 2003 Apr; 6(4):337-9. PubMed ID: 12839014
    [No Abstract]   [Full Text] [Related]  

  • 55. What's in a perspective?
    Glick HA
    Value Health; 2010; 13(1):2. PubMed ID: 19912594
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost of Cancer Drugs: Something Has To Give.
    Bender E
    Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.
    Garattini L; Grilli R; Scopelliti D; Mantovani L
    Pharmacoeconomics; 1995 Jan; 7(1):1-6. PubMed ID: 10155289
    [No Abstract]   [Full Text] [Related]  

  • 59. [The value of pharmaco-economics: the point of view of the drug industry].
    De Wever A
    Rev Med Liege; 1998 May; 53(5):236-41. PubMed ID: 9689874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The contribution of pharmaceutical companies: what's at stake for America. Executive summary from a report prepared by the Boston Consulting Group.
    Broshy E
    Ann N Y Acad Sci; 1994 Nov; 729():111-26; discussion 139-42. PubMed ID: 7998722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.